indapamide / Generic mfg. - LARVOL DELTA

Thiazide Diuretics Are Associated with a Higher Triglyceride-Glucose Index Than Calcium Channel Blockers in Hypertensive Patients. (PubMed, Int J Gen Med) - "A dose-stratified analysis within the diuretic group showed a significant dose-response relationship: higher hydrochlorothiazide (25 vs 12.5 mg/day) and indapamide (2.5 vs 1.25 mg/day) doses were both associated with significantly higher TyG index, fasting glucose, and uric acid levels. RAAS blocker plus thiazide/thiazide-like diuretic regimens were associated with a significantly higher TyG index and a less favorable metabolic profile than RAAS blocker plus CCB regimens, independent of multiple clinical confounders. Metabolic risk profiles should be considered when selecting antihypertensive combination therapy; prospective studies are needed to establish causality."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

Comparative Study on the Antihypertensive Efficacy of Compound Reserpine and Triamterene Tablets versus Spironolactone Combined with Indapamide in True Resistant Hypertension (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Hypertension

The effect of eplerenone vs irbesartan as first line therapy in obese hypertensive patients on left ventricular hypertrophy and diastolic dysfunction: echocardiographic results of the HEBRO randomized (ESC 2026) - "At 2 months and 4 months up-titration with amlodipine 5mg and indapamide 1.5mg respectively was taken place when mean ambulatory BP (ABPM) was over 130/80mmHg. The number of antihypertensive drugs was 1.8 ± 0.8 vs 1.9 ± 0.8, p=0.164.ConclusionsEchocardiographic assessment demonstrated that both irbesartan and eplerenone were associated with significant regression of left ventricular mass and improvement in diastolic function parameters over the 6-month follow-up period, with no significant difference between treatment groups in terms of LVMI reduction. Notably, eplerenone was associated with a significantly greater reduction in left atrial volume index compared with irbesartan, indicating a more pronounced effect on left atrial remodeling."

Clinical • Cardiovascular • Hypertension

Six-month renal marker trajectories with azilsartan–indapamide versus azilsartan–nitrendipine in essential hypertension: a pragmatic comparative study (ESC 2026) - "Conclusion In this pragmatic comparative cohort, azilsartan combined with either indapamide or nitrendipine demonstrated similar short-term improvements in eGFR and reductions in microalbuminuria. The choice of add-on agent did not meaningfully alter short-term renal trajectory under azilsartan-based therapy."

Cardiovascular • Hypertension

Differential effects of azilsartan-based combinations on arterial stiffness and central hemodynamics in essential hypertension (ESC 2026) - "The comparative impact of different azilsartan-based combinations on structural and pulsatile components of vascular stiffness remains insufficiently explored.AimTo compare the effects of azilsartan plus nitrendipine (A+N) versus azilsartan plus indapamide (A+I) on carotid–femoral pulse wave velocity (cfPWV), central pulse pressure (cPP), and augmentation index (AIx) in patients with essential hypertension.MethodsIn this prospective comparative study, patients with essential hypertension received A+N (n=51) or A+I (n=50) for 6 months.Carotid–femoral PWV and central hemodynamic parameters were assessed at baseline and at 6 months using applanation tonometry. Within-group changes and between-group differences in delta values were analyzed.ResultsBoth treatment regimens were associated with significant reductions in cfPWV.In the A+N group, PWV decreased from 10.57 m/s to 7.37 m/s (Δ −3.20 m/s; p<0.000001).In the A+I group, PWV decreased from 9.59 m/s to 7.36 m/s (Δ −2.23..."

Cardiovascular • Hypertension

Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial (ESC 2026) - "Participants were randomised to a triple single-pill combination of telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mg or matching placebo, in addition to usual care, with a mean follow-up of 3 years. Similar reductions were observed for diastolic BPV across SD (−0.84 mmHg; 95% CI −1.24 to −0.43; p<0.001), CV (−0.47%; 95% CI −0.92 to −0.02; p=0.039) and ARV (−0.84 mmHg; 95% CI −1.39 to −0.30; p=0.003), with no difference in VIM (−0.07; 95% CI −0.44 to 0.30; p=0.70).CONCLUSIONSIn patients with prior intracerebral haemorrhage receiving usual care, a low-dose triple single-pill combination reduced SD, CV and ARV of systolic and diastolic BP variability compared with placebo, but not VIM. As VIM adjusts for mean BP, the lack of a significant difference in VIM indicates that reductions in SD, CV and ARV were predominantly attributable to mean BP lowering."

Cardiovascular

Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy (ESC 2026) - "Purpose To assess whether AI-guided digital lifestyle support improves BP control when added to newly initiated fixed dual therapy with azilsartan medoxomil and indapamide...Conclusion In newly treated hypertensive patients receiving fixed dual therapy, AI-guided digital lifestyle support provided modest additional BP reduction and improved metabolic parameters over 12 weeks. Digital behavioral augmentation may represent a scalable adjunct to early hypertension control."

Cardiovascular • Hypertension

Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial (ESC 2026) - "At 2 and 4 months, stepwise up-titration with amlodipine 5 mg and indapamide 1.5 mg, respectively, was performed if mean ABPM remained >130/80 mmHg. Conclusion In obese hypertensive patients, first-line treatment with eplerenone was not associated with excess renal function decline or clinically significant hyperkalemia compared with irbesartan. These findings support the renal safety of MRA-based first-line therapy in this population."

Clinical • Cardiovascular • Hypertension

Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post hoc analysis of the BaxHTN trial (ESC 2026) - "In this analysis, patients were categorised by diuretic dose into low (≤0.5 defined daily dose [DDD]: e.g. indapamide ≤1.25 mg; chlortalidone ≤12.5 mg; hydrochlorothiazide ≤12.5 mg) and standard (defined as >0.5 DDD for this analysis) dose groups. Safety profiles were similar between groups, including discontinuation due to hyperkalaemia. Further data are needed to understand baxdrostat’s effect in patients without diuretics."

Clinical • Retrospective data • Cardiovascular • Hypertension

Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial (ESC 2026) - "At 2 months and 4 months up-titration with amlodipine 5mg and indapamide 1.5mg respectively was taken place when mean ambulatory BP (ABPM) was over 130/80mmHg. At 6 months, mean ambulatory BP reduction was -17.5/-9.6 mmHg ± 12.0/6.7 in the irbesartan vs. -19.0/-9.0 mmHg ± 12.6/8.2 in the eplerenone arm, p=0.463 and p=0.611 respectively. At 6 months, the number of antihypertensive drugs was 1.8 ± 0.8 vs 1.9 ± 0.8, p=0.164.ConclusionAt 6 months, eplerenone-based antihypertensive strategy is non-inferior compared to irbesartan-based strategy regarding reducing ABPM, under the same number of antihypertensive medications, accompanied by no difference in safety and renal function preservance."

Clinical • Cardiovascular • Hypertension

Vascular stiffness–integrated ai model improves discrimination of poor responders to azilsartan–indapamide therapy (ESC 2026) - "An interpretable AI model integrating vascular stiffness and metabolic/renal parameters improves identification of poor responders to azilsartan–indapamide beyond baseline SBP and supports precision phenotyping with feasible offline bedside deployment."

Cardiovascular • Hypertension

Efficacy and safety of zilebesiran for inadequately controlled hypertension: a systematic review and meta-analysis (ESC 2026) - "The placebo-adjusted least-squares mean difference in SBP reduction ranged from -4.0 mmHg (95% CI -7.6 to -0.3) in the olmesartan cohort to 12.1 mmHg (95% CI - 16.5 to -7.6) in the indapamide cohort. Single-dose subcutaneous zilebesiran as an add-on therapy provides significant antihypertensive efficacy in adults with uncontrolled hypertension. However, this benefit is accompanied by increased risks of hyperkalaemia and renal function decline. These findings highlight the potential of RNA interference therapeutics but underscore the need for careful monitoring of renal parameters."

Retrospective data • Review • Cardiovascular • Hypertension • Hypotension

A novel case of phenotypic evolution in indapamide-associated severe cutaneous adverse reaction with serial histopathological progression from acute generalised exanthematous pustulosis-like eruption to toxic epidermal necrolysis. (EADV 2026) - No abstract available

Clinical • Immunology • Steven-Johnson Syndrome

INDAMS: Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Eva M.M. Strijbis

New P2 trial • CNS Disorders • Multiple Sclerosis

Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence. (PubMed, Am J Cardiovasc Drugs) - "In this long-term, real-world study, SPC use was associated with better adherence, reduced HCRU, and lower healthcare costs compared with FPC regimens. These economic benefits were evident within 1 year and may yield substantial long-term savings for national health systems, given the high prevalence and chronic nature of hypertension."

HEOR • Journal • Real-world evidence • Cardiovascular • Hypertension

Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records. (PubMed, Int J Hypertens) - "Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Cough • Gout • Hypertension • Inflammatory Arthritis • Respiratory Diseases • Rheumatology

Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data. (PubMed, Front Pharmacol) - "Monthly procurement data for four NVBP antihypertensive drugs (Olmesartan Medoxomil, Candesartan Cilexetil, Terazosin Hydrochloride, and Indapamide) were collected from January 2019 to April 2021, covering 16 months before and 12 months after policy implementation (May 1, 2020). These findings, based on procurement records rather than patient-level data, suggest that price reductions alone may not ensure consistent procurement patterns. Strengthening supply chain resilience and aligning procurement schedules with clinical demand may support more stable drug supply in disadvantaged regions."

Journal • Cardiovascular • Hypertension

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial. (PubMed, J Urol) - "For the selective arm, diet and pharmacologic treatments, which included indapamide, potassium citrate, and/or allopurinol, were tailored based on urine testing at baseline and 4 weeks. Similarly, there were no significant differences at 8 weeks in urine volume and pH, or in excretion of calcium, oxalate, citrate, uric acid, and sodium. In this short-term trial among individuals at high-risk for stone recurrence, there was no statistically significant difference in the urinary stone risk comparing an empiric versus selective strategy for kidney stone prevention."

Journal • Nephrology • Renal Calculi • Urolithiasis

Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population (clinicaltrials.gov) - P=N/A | N=690 | Completed | Sponsor: Qilu Hospital of Shandong University

New trial • Cardiovascular • Congestive Heart Failure

In brief: Widaplik - another three-drug combination for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

Phenotype and management of infantile hypercalcemia type 1 in young adults: a case series (ERA 2026) - "For the third patient we recommended indapamide. The role of rifampin in HCINF1 therapy remains to be established and require further investigation. Image CT scan from the second patient with HCINF1 showing medullary nephrocalcinosis and left kidney cyst."

Clinical • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease • CYP24A1 • CYP3A4

Drug-Induced Hyponatremia Surveillance: A disproportionality analysis based on FAERs database. (PubMed, Pak J Med Sci) - "Five drugs demonstrated the highest cases counts: furosemide (n=1,560), hydrochlorothiazide (n=1049), sertraline (n=899), omeprazole(n=864), citalopram (n=738). The pharmacovigilance analysis identified five substances exhibiting the strongest association signals: indapamide (ROR=91.46, 95% CI 83.38-100.32), hydrochlorothiazide (ROR=46.79, 95% CI 43.96-49.81), desmopressin (ROR=34.08, 95% CI 31.49-36.89), oxcarbazepine (ROR=24.47, 95% CI 22.72-26.37), and furosemide (ROR=24.11, 95% CI 22.91-25.37). Nivolumab (36.92%), bortezomib (30.58%), and zoledronic (29.36%) exhibited the highest proportional occurrence of target adverse events involving fatal or life-threatening outcomes...We provide a list of drugs with risk signals for Hyponatremia. In clinical practice, it is helpful to identify the culprit drug early, and prevent it from further aggravation into a serious condition."

Journal • Cardiovascular • Heart Failure

TRACKING THIAZIDE THERAPY TREATMENT PATTERNS IN RECURRENT STONE FORMERS USING ON-TREATMENT 24-HOUR URINE ANALYSIS (AUA 2026) - "We included those prescribed a thiazide diuretic (hydrochlorothiazide, chlorthalidone, or indapamide) within 6 months of urine collection and who had a follow-up collection 30–180 days after their first prescription fill. Although underutilized, on-treatment testing provides clinically actionable information in the management of patients with kidney stones. Biochemical response to thiazide therapy influenced prescribing decisions, including continuation, dosage adjustment, and medication class switching. Greater uptake of guideline-recommended on-treatment testing may enhance individualized care for stone formers and optimize the use of preventive pharmacologic therapy."

Nephrology • Renal Calculi

Urinary supersaturation in a Randomized trial among Individuals with Nephrolithiasis comparing Empiric versus selective therapy (URINE) (AUA 2026) - "For the selective arm, diet and pharmacologic treatments, which included indapamide, potassium citrate, and/or allopurinol, were tailored based on urine testing at baseline and additionally at 4 weeks. This short-term trial found that among individuals at high-risk for stone recurrence, there was no difference in the urinary stone risk comparing an empiric versus a selective diet and pharmacologic strategy for kidney stone prevention."

Clinical • Nephrology • Renal Calculi • Urolithiasis